Chronic Kidney Disease Drugs Market to Reach US$ 19.4 Billion by 2031 at 6.6% CAGR, Led by North America with 38% Share

The Global Chronic Kidney Disease (CKD) Drugs Market was valued at US$ 10,923.29 million in 2021 and is projected to reach US$ 19,427.41 million by 2031, growing at a CAGR of 6.6% during the forecast period 2024-2031. The market is expanding steadily due to the rising prevalence of diabetes, hypertension, and aging populations worldwide, key risk factors driving the incidence of chronic kidney disease. Increased awareness, early diagnosis, and improved access to treatment options are further boosting demand for effective CKD therapeutics. Advancements in drug development, particularly in anemia management, mineral bone disorder treatment, and renoprotective therapies, are significantly contributing to market growth.

Growing investment by pharmaceutical companies, strong regulatory support for novel drug approvals, and an expanding pipeline of next-generation CKD therapies are strengthening market outlook. The shift toward combination treatments, personalized medicine, and long-acting formulations is enhancing patient outcomes and adherence. Regions such as North America and Europe continue to lead due to advanced healthcare infrastructure, while Asia-Pacific holds high growth potential driven by increasing CKD burden and improving healthcare access.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/chronic-kidney-disease-drugs-market?saikumar

The Chronic Kidney Disease (CKD) Drugs Market advances renal care with innovative therapies that slow disease progression, manage complications, and improve patient outcomes.

Key Developments

✅ October 2025: U.S. pharmaceutical companies expanded the rollout of advanced SGLT2 inhibitors and MRAs designed to slow CKD progression and reduce cardiovascular complications in high-risk patient groups.

✅ August 2025: American biotech firms accelerated development of late-stage CKD drug candidates targeting inflammation, fibrosis, and renal function decline, supported by strong clinical pipeline investments.

✅ April 2025: U.S. nephrology centers and hospitals integrated digital CKD management platforms combining optimized drug therapy, remote monitoring, and predictive analytics to improve patient outcomes.

Mergers & Acquisitions

✅ July 2025: A major U.S. pharmaceutical company acquired a renal therapeutics startup specializing in anti-fibrotic drug innovations to strengthen its CKD drug portfolio.

✅ May 2025: A leading American biotech firm completed the acquisition of a clinical-stage company developing RNA-based CKD therapies, boosting its next-generation renal treatment pipeline.

✅ January 2025: A U.S. healthcare corporation formed a strategic alliance with a nephrology research institute to co-develop novel CKD therapeutics aimed at early-stage disease intervention.

Key Players
AstraZeneca Plc | Sanofi S.A | F. Hoffmann-La Roche Ltd | Teva Pharmaceutical Industries Ltd | Kissei Pharmaceutical Co. | AbbVie Inc. | GlaxoSmithKline Plc (GSK) | Amgen Inc. | Akebia Therapeutics | Pfizer Inc.

Key Highlights
• AstraZeneca Plc - Holds an estimated 14.8% share, driven by its strong portfolio in renal and anemia therapies, continuous R&D investment, and expanding global patient base.

• Sanofi S.A - Accounts for around 11.6% share, supported by its expanding biologics pipeline, advanced treatment options for chronic and rare diseases, and strong global distribution network.

• F. Hoffmann-La Roche Ltd - Maintains approximately 10.9% share, fueled by its leading biologics expertise, innovative renal care treatments, and long-term focus on personalized medicine.

• Teva Pharmaceutical Industries Ltd - Represents nearly 9.2% share, backed by its extensive generic drug portfolio, affordability-driven market penetration, and broad geographic presence.

• Kissei Pharmaceutical Co. - Holds about 6.4% share, recognized for its targeted therapies in nephrology, urology, and metabolic disorders, alongside strong adoption in Asian markets.

• AbbVie Inc. - Accounts for approximately 12.1% share, driven by its robust immunology and specialty drug portfolio, innovative treatment lines, and expanding presence in chronic disease therapies.

• GlaxoSmithKline Plc (GSK) - Maintains around 8.7% share, supported by advancements in respiratory and chronic care medicines, strong clinical research, and wide healthcare reach.

• Amgen Inc. - Holds an estimated 11.3% share, powered by its biologics leadership, advanced therapies for anemia and chronic kidney disease, and strong biotechnology capabilities.

• Akebia Therapeutics - Represents roughly 4.5% share, known for its innovation in HIF-PH inhibitor drugs and growing footprint in anemia treatment for CKD patients.

• Pfizer Inc. - Accounts for about 10.5% share, fueled by its strong pharmaceutical research, expanding specialty drug portfolio, and global dominance in innovative therapeutic solutions.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=chronic-kidney-disease-drugs-market?saikumar

Market Drivers

- Rising global CKD burden driven by hypertension, diabetes and aging populations is accelerating demand for advanced therapeutics.

- Increasing adoption of personalized medicine and precision nephrology is enabling targeted drug development.

- Growing availability of combination therapies, improved dialysis-dependent drug protocols and expanded reimbursement support is strengthening market growth.

- Strong R&D pipeline focused on slowing disease progression, reducing inflammation and improving renal function is boosting long-term commercial potential.

Industrial Developments
- Pharmaceutical companies expanded clinical trials for next-generation SGLT2 inhibitors and non-steroidal mineralocorticoid receptor antagonists to improve kidney outcomes.

- Biotech firms advanced biologics targeting renal fibrosis and inflammation to enhance early-stage CKD treatment efficacy.

- Strategic collaborations between nephrology research institutes and pharma companies accelerated development of cardiometabolic-renal drug portfolios.

- Growing investment in AI-powered renal biomarker discovery to support precision dosing and earlier disease detection.

Regional Insights

North America holds over 38% of the market share, driven by "high CKD prevalence, strong reimbursement systems and rapid adoption of next-generation therapies."

Europe accounts for around 30% of the market due to "robust clinical research, rising awareness of renal health and increased use of advanced therapeutics."

Asia-Pacific is expanding at over 12% CAGR, supported by "a large patient pool, growing access to specialty care and accelerated approvals of novel CKD drugs."

Latin America and the Middle East & Africa together contribute below 10%, influenced by "gradual improvements in healthcare infrastructure and increased focus on chronic disease management."

Key Segments

➥ By Drug Class
ACE inhibitors are widely prescribed for managing hypertension and slowing kidney disease progression by relaxing blood vessels and reducing workload on the heart. Calcium channel blockers help control blood pressure and reduce cardiovascular strain by preventing calcium buildup in blood vessel walls. Beta-blockers support heart health by lowering heart rate and blood pressure, often used in patients with cardiovascular complications. Diuretics assist in removing excess fluid and sodium from the body, helping manage blood pressure and reduce kidney-related swelling. Erythropoiesis-stimulating agents are critical for treating anemia in chronic kidney disease patients by boosting red blood cell production. Others include combination therapies and emerging treatments targeting the underlying causes of kidney dysfunction.

➥ By Distribution Channel
Hospital pharmacies serve patients with advanced kidney disease, providing specialized medications and treatment guidance during inpatient and outpatient care. Retail pharmacies remain the primary access point for chronic medications, offering convenience and continuous availability for long-term CKD management. Online pharmacies are rapidly expanding, providing home delivery, subscription refills, and competitive pricing for essential kidney disease treatments. Others include specialty clinics and nephrology centers offering tailored drug regimens and patient-specific medication support.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/chronic-kidney-disease-drugs-market?saikumar

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.